Evidence-based medical and device therapies promote left ventricular reverse remodeling in approximately 40% of patients with dilated cardiomyopathy, leading to improved prognosis.
Left ventricular reverse remodeling is a dynamic and complex process occurring in a significant portion of DCM patients on optimal therapy, serving as both a measure of therapeutic effectiveness and a crucial prognostic tool.
Dilated Cardiomyopathy (DCM) has been classically considered a progressive disease of the heart muscle that inexorably progresses towards refractory heart failure, ventricular arrhythmias and heart transplant. However, the prognosis of DCM has significantly improved in the past few years, mostly as the result of successful therapy-induced reverse remodeling. Reverse remodeling is a complex process that involves not only the left ventricle, but also many other cardiac structures and it is now recognized both as a measure of therapeutic effectiveness and as an important prognostic tool. Nevertheless, several aspects of reverse remodeling remain unclear, including the best timing for its quantification, its predictors and its interaction with individual genetic backgrounds. In this review, we summarize our current understanding of reverse remodeling in patients with DCM and provide practical recommendations for the clinical management of this challenging patient population.
Merlo et al. (Thu,) conducted a review in Dilated Cardiomyopathy. Evidence-based medical and device therapies was evaluated. Evidence-based medical and device therapies promote left ventricular reverse remodeling in approximately 40% of patients with dilated cardiomyopathy, leading to improved prognosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: